Protein degradation: Prime time for PROTACs.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature Chemical Biology

• Publication date

  2015-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/nchembio.1887PMID 26284668
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Catalytic in vivo protein knockdown by small-molecule PROTACs.

  2015cited by this paper
• Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

  2015cited by this paper
• Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

  2015cited by this paper
• Phthalimide conjugation as a strategy for in vivo target protein degradation

  2015cited by this paper
• HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

  2015cited by this paper
• Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

  2014cited by this paper
• The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

  2014cited by this paper
• Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.

  2014cited by this paper
• Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

  2014cited by this paper
• Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

  2013cited by this paper
• Identification of a Primary Target of Thalidomide Teratogenicity

  2010cited by this paper
• Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

  2001cited by this paper
• Supplementary Methods

  year unknowncited by this paper

• Native Mass Spectrometry Analysis of Cullin RING Ubiquitin E3 Ligase Complexes in the Context of Targeted Protein Degradation

  2026cites this paper
• Stimuli-Activatable protein degraders for targeted Cancer therapy: From prodrug design to Nanoplatform applications.

  2026cites this paper
• Stability and Degradation-based Proteome Profiling Reveals Cannabidiol as a Promising CDC123-eIF2γ Inhibitor for Colorectal Cancer Therapy.

  2026cites this paper
• Recent Advances in the Development of Pro-PROTAC for Selective Protein Degradation

  2025cites this paper
• Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review

  2025cites this paper
• Opportunities in proximity modulation: Bridging academia and industry.

  2025cites this paper
• Cooperative Free Energy: Induced Protein–Protein Interactions and Cooperative Solvation in Ternary Complexes

  2025cites this paper
• ProLinker–Generator: Design of a PROTAC Linker Base on a Generation Model Using Transfer and Reinforcement Learning

  2025cites this paper
• Advancements in delivery Systems for Proteolysis-Targeting Chimeras (PROTACs): Overcoming challenges and expanding biomedical applications.

  2025cites this paper
• Self-assembled PROTACs enable glycoproteins degradation in the living cells

  2025cites this paper
• Predicting PROTAC-targeted Degradation and Designing Androgen Receptor Degraders with AiPROTAC

  2025cites this paper
• Unleashing the Power of Covalent Drugs for Protein Degradation

  2025cites this paper
• Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge.

  2025cites this paper
• From serendipity to strategy: molecular glue degraders in cancer therapeutics

  2025cites this paper
• Synthetic protein degradation circuits using programmable cleavage and ligation by Sortase A

  2025cites this paper
• ET-PROTACs: modeling ternary complex interactions using cross-modal learning and ternary attention for accurate PROTAC-induced degradation prediction

  2024cites this paper
• Recruitment to the Proteasome Is Necessary but Not Sufficient for Chemically Induced, Ubiquitin-Independent Degradation of Native Proteins.

  2024cites this paper
• Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

  2024cites this paper
• A Chemically Inducible Organelle Rerouting Assay to Probe Primary Cilium Assembly, Maintenance, and Disassembly in Cultured Cells.

  2024cites this paper
• A rare genetic Schuurs-Hoeijmakers syndrome (PACS1 syndrome)

  2024cites this paper
• CNS delivery of targeted protein degraders.

  2024cites this paper
• The emerging role of targeted protein degradation to treat and study cancer

  2024cites this paper
• Protease-Responsive Toolkit for Conditional Targeted Protein Degradation.

  2024cites this paper
• New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

  2024cites this paper
• Characteristic roadmap of linker governs the rational design of PROTACs

  2024cites this paper
• A Chemical Strategy for the Degradation of the Main Protease of SARS-CoV-2 in Cells.

  2023cites this paper
• PROTACs Targeting Epigenetic Proteins.

  2023cites this paper
• PROTAC derivatization of natural products for target identification and drug discovery: Design of evodiamine-based PROTACs as novel REXO4 degraders

  2023cites this paper
• Designing Bioorthogonal Reactions for Biomedical Applications

  2023cites this paper
• 3D based generative PROTAC linker design with reinforcement learning

  2023cites this paper
• The rise of degrader drugs.

  2023cites this paper
• Chemically Induced Degradation of Native Proteins by Direct Recruitment to the 26S Proteasome

  2023influential citation
• Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.

  2023cites this paper
• Targeted protein degradation might present a novel therapeutic approach in the fight against African trypanosomiasis

  2023cites this paper
• Degrading the signal amplifier: ITK as a target for targeted protein degradation.

  2023cites this paper
• Synthesis of Lathyrol PROTACs and Evaluation of Their Anti-Inflammatory Activities.

  2023cites this paper
• BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications

  2023cites this paper
• Strategies for Conditional Regulation of Proteins

  2023cites this paper
• PROTAC: A Novel drug delivery technology for targeting proteins in cancer cells.

  2022cites this paper
• Accelerated rational PROTAC design via deep learning and molecular simulations

  2022cites this paper
• Molecular Basis of the Schuurs–Hoeijmakers Syndrome: What We Know about the Gene and the PACS-1 Protein and Novel Therapeutic Approaches

  2022cites this paper
• The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation.

  2022cites this paper
• Generation of a live attenuated influenza A vaccine by proteolysis targeting

  2022cites this paper
• Kinetic Degradation of IMiD Molecular Glues and Their Target Families

  2022cites this paper
• Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory.

  2022cites this paper
• Harnessing the Therapeutic Potential of Biomacromolecules through Intracellular Delivery of Nucleic Acids, Peptides, and Proteins

  2022cites this paper
• PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids

  2022cites this paper
• Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.

  2022cites this paper
• Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond.

  2022cites this paper
• Cure and Long-Term Remission Strategies.

  2022cites this paper
• Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox

  2022cites this paper
• Chemoproteomic-enabled phenotypic screening.

  2021cites this paper
• High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics

  2021cites this paper
• The Rise of Molecular Glues.

  2021cites this paper
• A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts

  2021cites this paper
• Proteolysis-targeting Chimeras Technology for Selective Protein Degradation

  2021cites this paper
• Small-molecule degraders of cyclin-dependent kinase protein: a review.

  2021cites this paper
• Huntingtin structure is orchestrated by HAP40 and shows a polyglutamine expansion-specific interaction with exon 1

  2021cites this paper
• Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.

  2021cites this paper
• Targeted protein degraders from an oncologist point of view: the Holy Grail of cancer therapy?

  2021cites this paper
• Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants.

  2021cites this paper
• Translating PROTAC chemical series optimization into functional outcomes underlying BRD7 and BRD9 protein degradation

  2021cites this paper
• USP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates

  2021cites this paper
• Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.

  2021cites this paper
• Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.

  2021cites this paper
• Engineering single pan-specific ubiquibodies for targeted degradation of all forms of endogenous ERK protein kinase

  2021cites this paper
• Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.

  2021cites this paper
• Challenges and Opportunities in Cancer Drug Resistance.

  2020cites this paper
• Proteome editing using engineered proteins that hijack cellular quality control machinery

  2020cites this paper
• Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy.

  2020cites this paper
• PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network.

  2020cites this paper
• Proteolysis‐targeting chimeras in drug development: A safety perspective

  2020cites this paper
• Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.

  2020cites this paper
• A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer

  2020cites this paper
• Biological roles of LSD1 beyond its demethylase activity

  2020cites this paper
• Targeted Protein Degradation: "The Gold Rush is On!"

  2020cites this paper
• The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L

  2020cites this paper
• LDB1 Enforces Stability on Direct and Indirect Oncoprotein Partners in Leukemia

  2020cites this paper
• Fluorophosphonate‐Based Degrader Identifies Degradable Serine Hydrolases by Quantitative Proteomics

  2020cites this paper
• Molecular mechanisms of thalidomide and its derivatives

  2020cites this paper
• DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

  2020cites this paper
• The ubiquitin ligase Cullin-1 associates with chromatin and regulates transcription of specific c-MYC target genes

  2020cites this paper
• Therapeutic implications of prion diseases

  2020cites this paper
• CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2

  2020cites this paper
• Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy

  2020cites this paper
• Targeted Protein Degradation Phenotypic Studies Using HaloTag CRISPR/Cas9 Endogenous Tagging Coupled with HaloPROTAC3

  2020cites this paper
• Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs

  2020cites this paper
• Hit/Lead Discovery

  2020cites this paper
• A tale of two tails - efficient profiling of protein degraders by specific functional and target engagement readouts

  2020cites this paper
• Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs

  2019cites this paper
• Proteolysis Targeting Chimeras for the selective degradation of Mcl-1/Bcl-2 derived from nonselective target binding ligands.

  2019cites this paper
• A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis

  2019cites this paper
• Degradation of proteins by PROTACs and other strategies

  2019cites this paper
• Protein-slaying drugs could be the next blockbuster therapies

  2019cites this paper
• PROTACs: great opportunities for academia and industry

  2019cites this paper
• Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs

  2019cites this paper
• A novel cereblon modulator for targeted protein degradation.

  2019cites this paper
• Live cell kinetic analysis of the LMO2/LDB1 leukemogenic protein complex reveals a hierarchy of turnover with implications for complex assembly

  2019cites this paper
• A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

  2019cites this paper
• Bifunctional chemical probes inducing protein-protein interactions.

  2019cites this paper